HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,205,739 | +8.4% | 633,658 | +2.4% | 0.02% | +11.8% |
| Q2 2023 | $22,330,211 | +10.4% | 619,080 | +16.6% | 0.02% | +6.2% |
| Q1 2023 | $20,232,948 | -40.6% | 530,806 | -11.4% | 0.02% | -42.9% |
| Q4 2022 | $34,074,166 | +36.8% | 598,843 | -4.9% | 0.03% | +27.3% |
| Q3 2022 | $24,901,000 | -7.5% | 629,756 | +2.9% | 0.02% | 0.0% |
| Q2 2022 | $26,918,000 | +20.5% | 611,755 | +9.2% | 0.02% | +46.7% |
| Q1 2022 | $22,343,000 | +9.0% | 560,254 | +9.9% | 0.02% | +15.4% |
| Q4 2021 | $20,504,000 | +11.9% | 509,907 | +13.2% | 0.01% | 0.0% |
| Q3 2021 | $18,331,000 | -4.2% | 450,624 | +6.9% | 0.01% | 0.0% |
| Q2 2021 | $19,138,000 | +9.3% | 421,453 | +0.3% | 0.01% | 0.0% |
| Q1 2021 | $17,517,000 | -7.9% | 420,171 | -5.6% | 0.01% | -13.3% |
| Q4 2020 | $19,016,000 | +67.1% | 445,237 | +2.8% | 0.02% | +50.0% |
| Q3 2020 | $11,382,000 | -12.8% | 433,087 | -11.1% | 0.01% | -16.7% |
| Q2 2020 | $13,058,000 | +67.8% | 487,053 | +12.6% | 0.01% | +33.3% |
| Q1 2020 | $7,781,000 | -19.1% | 432,497 | -20.3% | 0.01% | 0.0% |
| Q4 2019 | $9,618,000 | +11.0% | 542,463 | -2.9% | 0.01% | 0.0% |
| Q3 2019 | $8,661,000 | -6.8% | 558,391 | +3.3% | 0.01% | 0.0% |
| Q2 2019 | $9,291,000 | +37.3% | 540,775 | +28.7% | 0.01% | +28.6% |
| Q1 2019 | $6,767,000 | +10.9% | 420,334 | +0.8% | 0.01% | 0.0% |
| Q4 2018 | $6,101,000 | +68.2% | 416,996 | +108.9% | 0.01% | +75.0% |
| Q3 2018 | $3,627,000 | -17.1% | 199,617 | -23.1% | 0.00% | 0.0% |
| Q2 2018 | $4,377,000 | -41.6% | 259,445 | -32.1% | 0.00% | -50.0% |
| Q1 2018 | $7,490,000 | -33.1% | 382,350 | -30.9% | 0.01% | -27.3% |
| Q4 2017 | $11,204,000 | +133.8% | 552,991 | +100.4% | 0.01% | +120.0% |
| Q3 2017 | $4,793,000 | +239.0% | 275,939 | +150.2% | 0.01% | +400.0% |
| Q2 2017 | $1,414,000 | -13.8% | 110,276 | -12.9% | 0.00% | -50.0% |
| Q1 2017 | $1,641,000 | +30.4% | 126,655 | -0.5% | 0.00% | +100.0% |
| Q4 2016 | $1,258,000 | -32.1% | 127,327 | -17.0% | 0.00% | -50.0% |
| Q3 2016 | $1,853,000 | +31.6% | 153,402 | -6.0% | 0.00% | 0.0% |
| Q2 2016 | $1,408,000 | -27.3% | 163,184 | -20.2% | 0.00% | 0.0% |
| Q1 2016 | $1,938,000 | -71.8% | 204,611 | -48.4% | 0.00% | -75.0% |
| Q4 2015 | $6,876,000 | +51.8% | 396,771 | +17.7% | 0.01% | +33.3% |
| Q3 2015 | $4,529,000 | +139.0% | 337,211 | +301.9% | 0.01% | +200.0% |
| Q2 2015 | $1,895,000 | +57.7% | 83,904 | -0.3% | 0.00% | +100.0% |
| Q1 2015 | $1,202,000 | +29.1% | 84,170 | -12.7% | 0.00% | 0.0% |
| Q4 2014 | $931,000 | +11.2% | 96,434 | +4.9% | 0.00% | 0.0% |
| Q3 2014 | $837,000 | -2.3% | 91,968 | +6.0% | 0.00% | 0.0% |
| Q2 2014 | $857,000 | -7.6% | 86,727 | +18.8% | 0.00% | 0.0% |
| Q1 2014 | $927,000 | -17.7% | 72,980 | -2.9% | 0.00% | 0.0% |
| Q4 2013 | $1,126,000 | – | 75,140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |